SELLAS Life Sciences Group Inc buy BiotechBee
Start price
03:01
/
60%
€1.07
Target price
30.04.27
€1.50
Performance (%)
-
Price
-
-
Summary
This prediction has just been started. It does not have a price yet.. This prediction currently runs until 30.04.27. The prediction end date can be changed by BiotechBee at any time.SELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
Performance without dividends (%)
| Name | 1w |
|---|---|
| SELLAS Life Sciences Group Inc | - |
| iShares Core DAX® | -3.429% |
| iShares Nasdaq 100 | -6.121% |
| iShares Nikkei 225® | -7.364% |
| iShares S&P 500 | -4.366% |
According to BiotechBee what are the pros and cons of SELLAS Life Sciences Group Inc for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year